New drug trial offers hope for painful skin blistering disease
NCT ID NCT07210554
Summary
This study is testing whether an injectable drug called stapokibart can help control moderate to severe bullous pemphigoid, a condition that causes painful, itchy skin blisters. Researchers will compare stapokibart against a placebo (inactive injection) in 200 adults to see if it can lead to sustained remission, allowing patients to stop oral steroids. The main goal is to see if participants can achieve and maintain clear or nearly clear skin without needing rescue treatments for 36 weeks.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BULLOUS PEMPHIGOID (BP) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Peking University First Hospital
Beijing, Beijing Municipality, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.